Your Health, We Care
Cibinqo is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.
Limitations of Use Cibinqo is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or other immunosuppressants.
from FDA，2023.12
This article discusses the applicable population and clinical use of abuxitinib.···【more】
Release date：2025-05-19Recommended：96
The medical community's exploration of new targeted drugs continues to drive···【more】
Release date：2025-05-16Recommended：95
A new class of oral drugs is changing the treatment landscape for specific infla···【more】
Release date：2025-05-16Recommended：629
